Figure 3 shows that, while there were no or small differences in discontinuation rates between subgroups according to status of ASCVD, chronic kidney disease and heart failure among users of GLP-1 receptor agonists, discontinuation rates were higher among those with normal weight vs other weight categories. Here, GLP1R is linked to chronic kidney disease.